Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

335 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Tumor characteristics and detection method in the MRISC screening program for the early detection of hereditary breast cancer.
Kriege M, Brekelmans CT, Peterse H, Obdeijn IM, Boetes C, Zonderland HM, Muller SH, Kok T, Manoliu RA, Besnard AP, Tilanus-Linthorst MM, Seynaeve C, Bartels CC, Meijer S, Oosterwijk JC, Hoogerbrugge N, Tollenaar RA, de Koning HJ, Rutgers EJ, Klijn JG. Kriege M, et al. Among authors: hoogerbrugge n. Breast Cancer Res Treat. 2007 May;102(3):357-63. doi: 10.1007/s10549-006-9341-6. Epub 2006 Oct 19. Breast Cancer Res Treat. 2007. PMID: 17051427
Randomized trial of a shared decision-making intervention consisting of trade-offs and individualized treatment information for BRCA1/2 mutation carriers.
van Roosmalen MS, Stalmeier PF, Verhoef LC, Hoekstra-Weebers JE, Oosterwijk JC, Hoogerbrugge N, Moog U, van Daal WA. van Roosmalen MS, et al. Among authors: hoogerbrugge n. J Clin Oncol. 2004 Aug 15;22(16):3293-301. doi: 10.1200/JCO.2004.05.066. J Clin Oncol. 2004. PMID: 15310772 Free article. Clinical Trial.
Phenotypic expression of double heterozygosity for BRCA1 and BRCA2 germline mutations.
Leegte B, van der Hout AH, Deffenbaugh AM, Bakker MK, Mulder IM, ten Berge A, Leenders EP, Wesseling J, de Hullu J, Hoogerbrugge N, Ligtenberg MJ, Ardern-Jones A, Bancroft E, Salmon A, Barwell J, Eeles R, Oosterwijk JC. Leegte B, et al. Among authors: hoogerbrugge n. J Med Genet. 2005 Mar;42(3):e20. doi: 10.1136/jmg.2004.027243. J Med Genet. 2005. PMID: 15744030 Free PMC article. Review. No abstract available.
The decision evaluation scales.
Stalmeier PF, Roosmalen MS, Verhoef LC, Hoekstra-Weebers JE, Oosterwijk JC, Moog U, Hoogerbrugge N, van Daal WA. Stalmeier PF, et al. Among authors: hoogerbrugge n. Patient Educ Couns. 2005 Jun;57(3):286-93. doi: 10.1016/j.pec.2004.07.010. Patient Educ Couns. 2005. PMID: 15893210 Free article.
A DGGE system for comprehensive mutation screening of BRCA1 and BRCA2: application in a Dutch cancer clinic setting.
van der Hout AH, van den Ouweland AM, van der Luijt RB, Gille HJ, Bodmer D, Brüggenwirth H, Mulder IM, van der Vlies P, Elfferich P, Huisman MT, ten Berge AM, Kromosoeto J, Jansen RP, van Zon PH, Vriesman T, Arts N, Lange MB, Oosterwijk JC, Meijers-Heijboer H, Ausems MG, Hoogerbrugge N, Verhoef S, Halley DJ, Vos YJ, Hogervorst F, Ligtenberg M, Hofstra RM. van der Hout AH, et al. Among authors: hoogerbrugge n. Hum Mutat. 2006 Jul;27(7):654-66. doi: 10.1002/humu.20340. Hum Mutat. 2006. PMID: 16683254
Factors affecting sensitivity and specificity of screening mammography and MRI in women with an inherited risk for breast cancer.
Kriege M, Brekelmans CT, Obdeijn IM, Boetes C, Zonderland HM, Muller SH, Kok T, Manoliu RA, Besnard AP, Tilanus-Linthorst MM, Seynaeve C, Bartels CC, Kaas R, Meijer S, Oosterwijk JC, Hoogerbrugge N, Tollenaar RA, Rutgers EJ, de Koning HJ, Klijn JG. Kriege M, et al. Among authors: hoogerbrugge n. Breast Cancer Res Treat. 2006 Nov;100(1):109-19. doi: 10.1007/s10549-006-9230-z. Epub 2006 Jun 22. Breast Cancer Res Treat. 2006. PMID: 16791481
335 results